We explore current treatment strategies-including well-known drugs such as Tamoxifen and Fulvestrant, as well as aromatase inhibitors-and explain how these therapies work and why resistance sometimes develops. This article also looks at emerging approaches, like oral estrogen receptor degraders (SERDs), combination therapies, and precision medicine techniques that tailor treatment based on each patient's unique genetic profile. Altogether, these developments represent a major step forward in our understanding and treatment of ER+ breast cancer.

Postoperatively, the patient received TC(docetaxel+cyclophosphamide) chemotherapy, total breast irradiation, and tamoxifen for 10 years. Considering the different subtypes and absence of other lesions, the patient was considered to have latent breast cancer as a new lesion. Chemotherapy, including anti- HER2 therapy, radiotherapy, and endocrine therapy, was administered as adjuvant treatment.

Postoperatively, the patient was started on tamoxifen, and she remains recurrence-free to date. This case underscoring the importance of careful pre-treatment assessment of malignancy.

Postoperatively, tamoxifen, a CDK4/6 inhibitor, and radiotherapy were administered...Despite initiating weekly paclitaxel plus bevacizumab, the disease progressed rapidly, and she died 4 months later. Notably, OMS symptoms did not recur. This case highlights paraneoplastic OMS as an initial manifestation of breast cancer, with neurological improvement following systemic therapy.

P2, N=231, Completed, ETOP IBCSG Partners Foundation | Recruiting --> Completed | Trial completion date: Jun 2026 --> Sep 2025 | Trial primary completion date: Jun 2026 --> Sep 2025

Here, we compare adenovirus-delivered Cre with tamoxifen-inducible CreER systems in models targeting luminal mammary epithelial cells for p53-loss...Despite similar tumor latencies across induction strategies, our findings demonstrate that adenoviral infection exerts long-term immunological effects that can confound interpretation of immune dynamics during early mammary tumorigenesis. These results emphasize the importance of induction-method selection when using genetically engineered mouse models to study cancer-immune interactions.

P1, N=136, Recruiting, Genentech, Inc. | Not yet recruiting --> Recruiting

This study provides the first human evidence with long-term ET administration to reveal that, besides genetic profiles, the gut microbiota is another critical factor that we should consider in the influence and prediction of breast cancer recurrence in the future.

Treatment principles for MBC mirror those of female breast cancer and include mastectomy, endocrine therapy (tamoxifen), radiotherapy, and systemic therapy as indicated...This case highlights the rarity of EPC with a mixed invasive component in men and underscores the importance of comprehensive morphologic and immunophenotypic evaluation. Increased reporting of such cases will improve understanding and management of male breast malignancies.

In this study, CA800-PR was newly developed for the treatment of hormone receptor-positive breast cancer unlike conventional drugs such as tamoxifen and aromatase inhibitors...Comparing with the traditional hormone therapies aimed at controlling tumor growth or preventing recurrence post-surgery, the tumor-targeted NIR fluorescent dye CA800-PR alone can be effectively used as a multifunctional antitumor agent directly inducing apoptosis in both MCF-7 cells and xenograft tumors. This work provides a promising alternative to hormone therapy-related breast cancer for future clinical applications.

Doxorubicin (DOX) entrapped hydrogel (DOX-Gel) significantly induced the anti-tumour responses with enhanced survival in different syngeneic murine tumour models. We demonstrated that DOX-GMP-Gel therapy activates the antitumour T cell immunity and generates a memory response to clear distant tumours. Our study provides a systemic design of long-lasting low molecular hydrogel to deliver the combination of immunostimulatory adjuvants and immunogenic cell death-inducing agents, offering a promising approach to modulate the tumour microenvironment for enhanced cancer therapy.

This work establishes NUP62 as a prognostic marker, revealing its dual function in promoting ERα-positive tumorigenesis and conferring endocrine resistance. These findings suggest that therapeutic targeting of NUP62 could be a viable strategy to enhance tamoxifen response and combat resistance in ERα-positive breast cancer.